Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

Mads Ravnborg; K Bendtzen; O Christensen; P E H Jensen; D Hesse; M G Tovey; P S Sørensen

doi:10.1177/1352458508099476

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

Mads Ravnborg, K Bendtzen, O Christensen, P E H Jensen, D Hesse, M G Tovey, P S Sørensen

Department of Clinical Medicine

18 Citations (Scopus)

Abstract

It is unknown whether immunosuppression of patients who have developed interferon-beta (IFN-beta) neutralizing antibodies (NAbs) hastens disappearance of NAbs in the blood.

Original language	English
Journal	Multiple Sclerosis
Volume	15
Issue number	3
Pages (from-to)	323-8
Number of pages	6
ISSN	1352-4585
DOIs	https://doi.org/10.1177/1352458508099476 https://doi.org/10.1177/1352458508099476
Publication status	Published - 1 Mar 2009

Access to Document

Cite this

Ravnborg, M., Bendtzen, K., Christensen, O., Jensen, P. E. H., Hesse, D., Tovey, M. G., & Sørensen, P. S. (2009). Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Multiple Sclerosis, 15(3), 323-8. https://doi.org/10.1177/1352458508099476, https://doi.org/10.1177/1352458508099476

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. / Ravnborg, Mads; Bendtzen, K; Christensen, O et al.

In: Multiple Sclerosis, Vol. 15, No. 3, 01.03.2009, p. 323-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Ravnborg, M, Bendtzen, K, Christensen, O, Jensen, PEH, Hesse, D, Tovey, MG & Sørensen, PS 2009, 'Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis', Multiple Sclerosis, vol. 15, no. 3, pp. 323-8. https://doi.org/10.1177/1352458508099476, https://doi.org/10.1177/1352458508099476

@article{02d2d2c05c0f11df928f000ea68e967b,

title = "Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis",

abstract = "It is unknown whether immunosuppression of patients who have developed interferon-beta (IFN-beta) neutralizing antibodies (NAbs) hastens disappearance of NAbs in the blood.",

author = "Mads Ravnborg and K Bendtzen and O Christensen and Jensen, {P E H} and D Hesse and Tovey, {M G} and S{\o}rensen, {P S}",

year = "2009",

month = mar,

day = "1",

doi = "10.1177/1352458508099476",

language = "English",

volume = "15",

pages = "323--8",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "3",

}

TY - JOUR

T1 - Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

AU - Ravnborg, Mads

AU - Bendtzen, K

AU - Christensen, O

AU - Jensen, P E H

AU - Hesse, D

AU - Tovey, M G

AU - Sørensen, P S

PY - 2009/3/1

Y1 - 2009/3/1

N2 - It is unknown whether immunosuppression of patients who have developed interferon-beta (IFN-beta) neutralizing antibodies (NAbs) hastens disappearance of NAbs in the blood.

AB - It is unknown whether immunosuppression of patients who have developed interferon-beta (IFN-beta) neutralizing antibodies (NAbs) hastens disappearance of NAbs in the blood.

U2 - 10.1177/1352458508099476

DO - 10.1177/1352458508099476

M3 - Journal article

C2 - 19028832

SN - 1352-4585

VL - 15

SP - 323

EP - 328

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 3

ER -

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

Abstract

Access to Document

Fingerprint

Cite this